Related Experiment Videos

Matrix metalloproteinases and TIMPs: properties and implications for the treatment of chronic obstructive pulmonary

T Cawston1, S Carrere, J Catterall

  • 1Department of Rheumatology, Department of Medicine, University of Newcastle, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.

Novartis Foundation Symposium
|February 24, 2001
PubMed

Insights

Matrix metalloproteinases (MMPs) degrade connective tissue. Inhibiting MMPs shows promise in preventing tissue breakdown, with new drugs being tested in clinical trials for diseases like COPD.

Area of Science:

  • Biochemistry
  • Pathology
  • Pharmacology

Background:

  • Matrix metalloproteinases (MMPs) are enzymes capable of degrading connective tissue.
  • Tissue inhibitors of metalloproteinases (TIMPs) regulate MMP activity.
  • Imbalances between MMPs and TIMPs contribute to tissue breakdown in various diseases.

Purpose of the Study:

  • To investigate the role of MMPs in connective tissue degradation.
  • To evaluate the therapeutic potential of MMP inhibitors.

Main Methods:

  • Utilized transgenic mouse models to study MMP function in vivo.
  • Assessed the efficacy of novel MMP inhibitors in vitro and in animal models.

Main Results:

  • MMP1 overexpression led to pulmonary emphysema in mice.
  • MMP12 knockout mice were protected from cigarette smoke-induced emphysema.
  • Developed MMP inhibitors demonstrated effectiveness in preventing tissue destruction in preclinical studies.

Conclusions:

  • MMPs play a significant role in the pathogenesis of diseases involving connective tissue destruction.
  • Specific MMP inhibitors are a promising therapeutic strategy for preventing tissue breakdown.
  • Further clinical trials are warranted to evaluate the efficacy of these inhibitors in patients.

Related Concept Videos